Axial length targets for myopia control

• Published in: Ophthalmic & physiological optics Vol. 41; no. 3; pp. 523 - 531
• Main Authors: Chamberlain, Paul, Lazon de la Jara, Percy, Arumugam, Baskar, Bullimore, Mark A
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2021; John Wiley and Sons Inc
• Subjects: Adolescent; Age composition; axial length; Axial Length, Eye - diagnostic imaging; Axial Length, Eye - physiopathology; Child; Children; Clinical trials; Contact lenses; Disease Management; Elongation; Female; Follow-Up Studies; Humans; Male; Myopia; Myopia - diagnosis; Myopia - physiopathology; myopia control; Physiology; Risk factors; Time Factors; myopia; axial length; children; myopia control; contact lenses
• ISSN: 0275-5408; 1475-1313; 1475-1313
• DOI: 10.1111/opo.12812

Purpose Both emmetropic and myopic eyes elongate throughout childhood. The goals of this study were to compare axial elongation among untreated progressing myopes, progressing myopes treated with a myopia control contact lens and emmetropes, in order to place axial elongation in the context of normal eye growth in emmetropic children, and to consider whether normal physiological eye growth places limits on what might be achieved with myopia control. Methods Axial elongation data were taken from the 3‐year randomised clinical trial of a myopia control dual‐focus (MiSight® 1 day) contact lens. These were compared with data for myopic and emmetropic children in two large cohort studies: the Orinda Longitudinal Study of Myopia (OLSM) and the Singapore Cohort Study of the Risk Factors for Myopia (SCORM). Each study's published equations were used to calculate annual axial elongation. Four virtual cohorts—myopic and emmetropic for each model—were created, each with the same age distribution as the MiSight clinical trial subjects and the predicted cumulative elongation calculated at years 1, 2 and 3 for myopes and emmetropes using both the OLSM and SCORM models. Results The untreated control myopes in the MiSight clinical trial showed mean axial elongation over 3 years (0.62 mm) similar to the virtual cohorts based on the OLSM (0.70 mm) and SCORM (0.65 mm) models. The predicted 3‐year axial elongation for the virtual cohorts of emmetropes was 0.24 mm for both the OLSM and SCORM models—similar to the mean 3‐year elongation in MiSight‐treated myopes (0.30 mm). Conclusions The 3‐year elongation in MiSight‐treated myopes approached that of virtual cohorts of emmetropes with the same age distribution. It is hypothesised that myopic axial elongation is superimposed on an underlying physiological axial elongation observed in emmetropic eyes, which reflects increases in body stature. We speculate that optically based myopia control treatments may minimise the myopic axial elongation but retain the underlying physiological elongation observed in emmetropic eyes.